Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOSEMITE phase 3 trial of zodasiran in adolescents and adults with homozygous familial hypercholesterolemia
MOH_2025-12-10_015529Phase 3Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Zodasiran with Placebo (2 arms). Started Dec 2025; status: recruiting.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on MOH_2025-12-10_015529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-10_015529.